Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats

Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine wh...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biological & pharmaceutical bulletin 2020/05/01, Vol.43(5), pp.859-863
Hauptverfasser: Kondo, Ryo, Nakano, Ayuki, Asano, Daiki, Morita, Akane, Arima, Shiho, Mori, Asami, Sakamoto, Kenji, Nagamitsu, Tohru, Nakahara, Tsutomu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 863
container_issue 5
container_start_page 859
container_title Biological & pharmaceutical bulletin
container_volume 43
creator Kondo, Ryo
Nakano, Ayuki
Asano, Daiki
Morita, Akane
Arima, Shiho
Mori, Asami
Sakamoto, Kenji
Nagamitsu, Tohru
Nakahara, Tsutomu
description Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine whether the abnormal vascular growth occurs in a manner dependent on the degree of the vascular defects. Vascular defects of two different degrees were created in the retina by subcutaneously treating neonatal rats with the VEGF receptor (VEGFR) tyrosine kinase inhibitor KRN633 on postnatal day (P) 4 and P5 (P4/5) or P7 and P8 (P7/8). The structure of the retinal vasculature changes was examined immunohistochemically. Prevention of vascular growth and regression of some preformed capillaries were observed on the next day, after completion of each treatment (i.e., P6 and P9). The vascular regrowth occurred as a result of eliminating the inhibitory effect on the VEGFR signaling pathway. KRN633 (P4/5)-treated rats exhibited a retinal vasculature with aggressive intravitreal neovascularization on P21. On the other hand, the appearance of tortuous arteries is a representative vascular pathological feature in retinas of KRN633 (P7/8)-treated groups. These results suggest that an interruption of the retinal vascular development at different time points induces different vascular pathological features in the retina. Pharmacological agents targeting the VEGF signaling pathway are useful for creating an abnormal retinal vasculature with various pathological features in order to evaluate the efficacy of anti-angiogenic compounds.
doi_str_mv 10.1248/bpb.b19-01065
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2399842490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2399842490</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-c7dc3228896ab590220ca030eb11436d851a87d1b7284f398a60d257e966e2103</originalsourceid><addsrcrecordid>eNpd0c1rFDEYBvAgil2rR68S8OJlar4nOS7rV6GglOo1ZDLvdrPMJGOSUfrfO7tbF_GSEPLjgfd9EHpNyRVlQr_vpu6qo6YhlCj5BK0oF20jGZVP0YoYqhtFpb5AL0rZE0JawvhzdMEZb7VUdIXSuospj27AP1zx8-Ay_raDmOrDBAWvS0k-uAo9_h3qDtcd4LswhniP0xZfxwo5z1MNKR7et1BD_DfpA_yCIU0jxIpDxLeulpfo2dYNBV493pfo-6ePd5svzc3Xz9eb9U3jhVK18W3vOWNaG-U6aQhjxDvCCXSUCq56LanTbU-7lmmx5UY7RXomWzBKAaOEX6J3p9wpp58zlGrHUDwMg4uQ5mIZN0YLJsyBvv2P7tOcl0GOql2MVGJRzUn5nErJsLVTDqPLD5YSe2jCLk3YpQl7bGLxbx5T526E_qz_rn4BmxPYl-ru4QxcrsEPcIwT3MrDcY49__qdyxYi_wMNAZuw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2397249564</pqid></control><display><type>article</type><title>Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Kondo, Ryo ; Nakano, Ayuki ; Asano, Daiki ; Morita, Akane ; Arima, Shiho ; Mori, Asami ; Sakamoto, Kenji ; Nagamitsu, Tohru ; Nakahara, Tsutomu</creator><creatorcontrib>Kondo, Ryo ; Nakano, Ayuki ; Asano, Daiki ; Morita, Akane ; Arima, Shiho ; Mori, Asami ; Sakamoto, Kenji ; Nagamitsu, Tohru ; Nakahara, Tsutomu</creatorcontrib><description>Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine whether the abnormal vascular growth occurs in a manner dependent on the degree of the vascular defects. Vascular defects of two different degrees were created in the retina by subcutaneously treating neonatal rats with the VEGF receptor (VEGFR) tyrosine kinase inhibitor KRN633 on postnatal day (P) 4 and P5 (P4/5) or P7 and P8 (P7/8). The structure of the retinal vasculature changes was examined immunohistochemically. Prevention of vascular growth and regression of some preformed capillaries were observed on the next day, after completion of each treatment (i.e., P6 and P9). The vascular regrowth occurred as a result of eliminating the inhibitory effect on the VEGFR signaling pathway. KRN633 (P4/5)-treated rats exhibited a retinal vasculature with aggressive intravitreal neovascularization on P21. On the other hand, the appearance of tortuous arteries is a representative vascular pathological feature in retinas of KRN633 (P7/8)-treated groups. These results suggest that an interruption of the retinal vascular development at different time points induces different vascular pathological features in the retina. Pharmacological agents targeting the VEGF signaling pathway are useful for creating an abnormal retinal vasculature with various pathological features in order to evaluate the efficacy of anti-angiogenic compounds.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b19-01065</identifier><identifier>PMID: 32378561</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>abnormal retinal vasculature ; Angiogenesis ; Animals ; Animals, Newborn ; Arteries ; Blindness ; Capillaries ; Enzyme inhibitors ; Hypoxia ; intravitreal neovascularization ; Neonates ; Phenotype ; Phenotypes ; Phenylurea Compounds - administration &amp; dosage ; Protein Kinase Inhibitors - administration &amp; dosage ; Protein-tyrosine kinase ; Quinazolines - administration &amp; dosage ; Rats, Sprague-Dawley ; Receptors, Vascular Endothelial Growth Factor - antagonists &amp; inhibitors ; Retina ; Retinal Vessels - drug effects ; Retinal Vessels - growth &amp; development ; Retinal Vessels - pathology ; Signal transduction ; Time Factors ; tortuous artery ; Vascular endothelial growth factor ; vascular endothelial growth factor receptor tyrosine kinase inhibitor ; Vascular endothelial growth factor receptors ; Vascularization</subject><ispartof>Biological and Pharmaceutical Bulletin, 2020/05/01, Vol.43(5), pp.859-863</ispartof><rights>2020 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c466t-c7dc3228896ab590220ca030eb11436d851a87d1b7284f398a60d257e966e2103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1877,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32378561$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kondo, Ryo</creatorcontrib><creatorcontrib>Nakano, Ayuki</creatorcontrib><creatorcontrib>Asano, Daiki</creatorcontrib><creatorcontrib>Morita, Akane</creatorcontrib><creatorcontrib>Arima, Shiho</creatorcontrib><creatorcontrib>Mori, Asami</creatorcontrib><creatorcontrib>Sakamoto, Kenji</creatorcontrib><creatorcontrib>Nagamitsu, Tohru</creatorcontrib><creatorcontrib>Nakahara, Tsutomu</creatorcontrib><title>Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats</title><title>Biological &amp; pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine whether the abnormal vascular growth occurs in a manner dependent on the degree of the vascular defects. Vascular defects of two different degrees were created in the retina by subcutaneously treating neonatal rats with the VEGF receptor (VEGFR) tyrosine kinase inhibitor KRN633 on postnatal day (P) 4 and P5 (P4/5) or P7 and P8 (P7/8). The structure of the retinal vasculature changes was examined immunohistochemically. Prevention of vascular growth and regression of some preformed capillaries were observed on the next day, after completion of each treatment (i.e., P6 and P9). The vascular regrowth occurred as a result of eliminating the inhibitory effect on the VEGFR signaling pathway. KRN633 (P4/5)-treated rats exhibited a retinal vasculature with aggressive intravitreal neovascularization on P21. On the other hand, the appearance of tortuous arteries is a representative vascular pathological feature in retinas of KRN633 (P7/8)-treated groups. These results suggest that an interruption of the retinal vascular development at different time points induces different vascular pathological features in the retina. Pharmacological agents targeting the VEGF signaling pathway are useful for creating an abnormal retinal vasculature with various pathological features in order to evaluate the efficacy of anti-angiogenic compounds.</description><subject>abnormal retinal vasculature</subject><subject>Angiogenesis</subject><subject>Animals</subject><subject>Animals, Newborn</subject><subject>Arteries</subject><subject>Blindness</subject><subject>Capillaries</subject><subject>Enzyme inhibitors</subject><subject>Hypoxia</subject><subject>intravitreal neovascularization</subject><subject>Neonates</subject><subject>Phenotype</subject><subject>Phenotypes</subject><subject>Phenylurea Compounds - administration &amp; dosage</subject><subject>Protein Kinase Inhibitors - administration &amp; dosage</subject><subject>Protein-tyrosine kinase</subject><subject>Quinazolines - administration &amp; dosage</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Vascular Endothelial Growth Factor - antagonists &amp; inhibitors</subject><subject>Retina</subject><subject>Retinal Vessels - drug effects</subject><subject>Retinal Vessels - growth &amp; development</subject><subject>Retinal Vessels - pathology</subject><subject>Signal transduction</subject><subject>Time Factors</subject><subject>tortuous artery</subject><subject>Vascular endothelial growth factor</subject><subject>vascular endothelial growth factor receptor tyrosine kinase inhibitor</subject><subject>Vascular endothelial growth factor receptors</subject><subject>Vascularization</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0c1rFDEYBvAgil2rR68S8OJlar4nOS7rV6GglOo1ZDLvdrPMJGOSUfrfO7tbF_GSEPLjgfd9EHpNyRVlQr_vpu6qo6YhlCj5BK0oF20jGZVP0YoYqhtFpb5AL0rZE0JawvhzdMEZb7VUdIXSuospj27AP1zx8-Ay_raDmOrDBAWvS0k-uAo9_h3qDtcd4LswhniP0xZfxwo5z1MNKR7et1BD_DfpA_yCIU0jxIpDxLeulpfo2dYNBV493pfo-6ePd5svzc3Xz9eb9U3jhVK18W3vOWNaG-U6aQhjxDvCCXSUCq56LanTbU-7lmmx5UY7RXomWzBKAaOEX6J3p9wpp58zlGrHUDwMg4uQ5mIZN0YLJsyBvv2P7tOcl0GOql2MVGJRzUn5nErJsLVTDqPLD5YSe2jCLk3YpQl7bGLxbx5T526E_qz_rn4BmxPYl-ru4QxcrsEPcIwT3MrDcY49__qdyxYi_wMNAZuw</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Kondo, Ryo</creator><creator>Nakano, Ayuki</creator><creator>Asano, Daiki</creator><creator>Morita, Akane</creator><creator>Arima, Shiho</creator><creator>Mori, Asami</creator><creator>Sakamoto, Kenji</creator><creator>Nagamitsu, Tohru</creator><creator>Nakahara, Tsutomu</creator><general>The Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20200501</creationdate><title>Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats</title><author>Kondo, Ryo ; Nakano, Ayuki ; Asano, Daiki ; Morita, Akane ; Arima, Shiho ; Mori, Asami ; Sakamoto, Kenji ; Nagamitsu, Tohru ; Nakahara, Tsutomu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-c7dc3228896ab590220ca030eb11436d851a87d1b7284f398a60d257e966e2103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>abnormal retinal vasculature</topic><topic>Angiogenesis</topic><topic>Animals</topic><topic>Animals, Newborn</topic><topic>Arteries</topic><topic>Blindness</topic><topic>Capillaries</topic><topic>Enzyme inhibitors</topic><topic>Hypoxia</topic><topic>intravitreal neovascularization</topic><topic>Neonates</topic><topic>Phenotype</topic><topic>Phenotypes</topic><topic>Phenylurea Compounds - administration &amp; dosage</topic><topic>Protein Kinase Inhibitors - administration &amp; dosage</topic><topic>Protein-tyrosine kinase</topic><topic>Quinazolines - administration &amp; dosage</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Vascular Endothelial Growth Factor - antagonists &amp; inhibitors</topic><topic>Retina</topic><topic>Retinal Vessels - drug effects</topic><topic>Retinal Vessels - growth &amp; development</topic><topic>Retinal Vessels - pathology</topic><topic>Signal transduction</topic><topic>Time Factors</topic><topic>tortuous artery</topic><topic>Vascular endothelial growth factor</topic><topic>vascular endothelial growth factor receptor tyrosine kinase inhibitor</topic><topic>Vascular endothelial growth factor receptors</topic><topic>Vascularization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kondo, Ryo</creatorcontrib><creatorcontrib>Nakano, Ayuki</creatorcontrib><creatorcontrib>Asano, Daiki</creatorcontrib><creatorcontrib>Morita, Akane</creatorcontrib><creatorcontrib>Arima, Shiho</creatorcontrib><creatorcontrib>Mori, Asami</creatorcontrib><creatorcontrib>Sakamoto, Kenji</creatorcontrib><creatorcontrib>Nagamitsu, Tohru</creatorcontrib><creatorcontrib>Nakahara, Tsutomu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological &amp; pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kondo, Ryo</au><au>Nakano, Ayuki</au><au>Asano, Daiki</au><au>Morita, Akane</au><au>Arima, Shiho</au><au>Mori, Asami</au><au>Sakamoto, Kenji</au><au>Nagamitsu, Tohru</au><au>Nakahara, Tsutomu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats</atitle><jtitle>Biological &amp; pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>43</volume><issue>5</issue><spage>859</spage><epage>863</epage><pages>859-863</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>Pathological angiogenesis is a leading cause of blindness in several retinal diseases. The key driving factor inducing pathological angiogenesis is the pronounced hypoxia leading to a marked, increased production of vascular endothelial growth factor (VEGF). The aim of this study was to determine whether the abnormal vascular growth occurs in a manner dependent on the degree of the vascular defects. Vascular defects of two different degrees were created in the retina by subcutaneously treating neonatal rats with the VEGF receptor (VEGFR) tyrosine kinase inhibitor KRN633 on postnatal day (P) 4 and P5 (P4/5) or P7 and P8 (P7/8). The structure of the retinal vasculature changes was examined immunohistochemically. Prevention of vascular growth and regression of some preformed capillaries were observed on the next day, after completion of each treatment (i.e., P6 and P9). The vascular regrowth occurred as a result of eliminating the inhibitory effect on the VEGFR signaling pathway. KRN633 (P4/5)-treated rats exhibited a retinal vasculature with aggressive intravitreal neovascularization on P21. On the other hand, the appearance of tortuous arteries is a representative vascular pathological feature in retinas of KRN633 (P7/8)-treated groups. These results suggest that an interruption of the retinal vascular development at different time points induces different vascular pathological features in the retina. Pharmacological agents targeting the VEGF signaling pathway are useful for creating an abnormal retinal vasculature with various pathological features in order to evaluate the efficacy of anti-angiogenic compounds.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>32378561</pmid><doi>10.1248/bpb.b19-01065</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-6158
ispartof Biological and Pharmaceutical Bulletin, 2020/05/01, Vol.43(5), pp.859-863
issn 0918-6158
1347-5215
language eng
recordid cdi_proquest_miscellaneous_2399842490
source J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry
subjects abnormal retinal vasculature
Angiogenesis
Animals
Animals, Newborn
Arteries
Blindness
Capillaries
Enzyme inhibitors
Hypoxia
intravitreal neovascularization
Neonates
Phenotype
Phenotypes
Phenylurea Compounds - administration & dosage
Protein Kinase Inhibitors - administration & dosage
Protein-tyrosine kinase
Quinazolines - administration & dosage
Rats, Sprague-Dawley
Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
Retina
Retinal Vessels - drug effects
Retinal Vessels - growth & development
Retinal Vessels - pathology
Signal transduction
Time Factors
tortuous artery
Vascular endothelial growth factor
vascular endothelial growth factor receptor tyrosine kinase inhibitor
Vascular endothelial growth factor receptors
Vascularization
title Abnormal Vascular Phenotypes Associated with the Timing of Interruption of Retinal Vascular Development in Rats
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T17%3A34%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abnormal%20Vascular%20Phenotypes%20Associated%20with%20the%20Timing%20of%20Interruption%20of%20Retinal%20Vascular%20Development%20in%20Rats&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Kondo,%20Ryo&rft.date=2020-05-01&rft.volume=43&rft.issue=5&rft.spage=859&rft.epage=863&rft.pages=859-863&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b19-01065&rft_dat=%3Cproquest_cross%3E2399842490%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2397249564&rft_id=info:pmid/32378561&rfr_iscdi=true